CLIOMMICS

Publikationen

2019

Chattopadhyay, S., Thomsen, H., Yadav, P., da Silva Filho, M. I., Weinhold, N., Nothen, M. M., Hoffman, P., Bertsch, U., Huhn, S., Morgan, G. J., Goldschmidt, H., Houlston, R., Hemminki, K.Forsti, A., 2019. Genome-wide interaction and pathway-based identification of key regulators in multiple myeloma. Commun Biol, 2, 89. doi.org/10.1038/s42003-019-0329-2

2018

Ali, M., Ajore, R., Wihlborg, A.-K., Niroula, A., Swaminathan, B., Johnsson, E., Stephens, O. W., Morgan, G., Meissner, T., Turesson, I., Goldschmidt, H., Mellqvist, U.-H., Gullberg, U., Hansson, M., Hemminki, K., Nahi, H., Waage, A., Weinhold, N.Nilsson, B., 2018. The multiple myeloma risk allele at 5q15 lowers ELL2 expression and increases ribosomal gene expression. Nat Commun, 9(1), 1649. doi.org/10.1038/s41467-018-04082-2

Bruyer, A., Maes, K., Herviou, L., Kassambara, A., Seckinger, A., Cartron, G., Rème, T., Robert, N., Requirand, G., Boireau, S., Müller-Tidow, C., Veyrune, J.-L., Vincent, L., Bouhya, S., Goldschmidt, H., Vanderkerken, K., Hose, D., Klein, B., De Bruyne, E.Moreaux, J., 2018. DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cells. Br. J. Cancer, 118(8), 1062-1073. doi.org/10.1038/s41416-018-0025-x

Campo, C., da Silva Filho, M. I., Weinhold, N., Mahmoudpour, S. H., Goldschmidt, H., Hemminki, K., Merz, M.Försti, A., 2018. Bortezomib-induced peripheral neuropathy: A genome-wide association study on multiple myeloma patients. Hematol Oncol, 36(1), 232-237. doi.org/10.1002/hon.2391

Chattopadhyay, S., Thomsen, H., da Silva Filho, M. I., Weinhold, N., Hoffmann, P., Nöthen, M. M., Marina, A., Jöckel, K.-H., Schmidt, B., Pechlivanis, S., Langer, C., Goldschmidt, H., Hemminki, K.Försti, A., 2018. Enrichment of B cell receptor signaling and epidermal growth factor receptor pathways in monoclonal gammopathy of undetermined significance: a genome-wide genetic interaction study. Mol. Med., 24(1), 30. doi.org/10.1186/s10020-018-0031-8

Chattopadhyay, S., Yu, H., Sud, A., Sundquist, J., Försti, A., Hemminki, A.Hemminki, K., 2018. Multiple myeloma: family history and mortality in second primary cancers. Blood Cancer J, 8(8), 75. doi.org/10.1038/s41408-018-0108-1

Ganzinger, M., Gietzelt, M., Karmen, C., Flores, B.Knaup, P., 2018. Implementing Systems Medicine: A Medical Informatics Perspective. Stud Health Technol Inform, 247, 875-879.

Gu, C., Holman, C., Sompallae, R., Jing, X., Tomasson, M., Hose, D., Seckinger, A., Zhan, F., Tricot, G., Goldschmidt, H., Yang, Y.Janz, S., 2018. Upregulation of FOXM1 in a subset of relapsed myeloma results in poor outcome. Blood Cancer J, 8(2), 22. doi.org/10.1038/s41408-018-0060-0

Herviou, L., Kassambara, A., Boireau, S., Robert, N., Requirand, G., Müller-Tidow, C., Vincent, L., Seckinger, A., Goldschmidt, H., Cartron, G., Hose, D., Cavalli, G.Moreaux, J., 2018. PRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDs. Clin Epigenetics, 10(1), 121. doi.org/10.1186/s13148-018-0554-4

Lehners, N., Becker, N., Benner, A., Pritsch, M., Löpprich, M., Mai, E. K., Hillengass, J., Goldschmidt, H.Raab, M.-S., 2018. Analysis of long-term survival in multiple myeloma after first-line autologous stem cell transplantation: impact of clinical risk factors and sustained response. Cancer Med, 7(2), 307-316. doi.org/10.1002/cam4.1283

Mahmoudpour, S. H., Bandapalli, O. R., da Silva Filho, M. I., Campo, C., Hemminki, K., Goldschmidt, H., Merz, M.Försti, A., 2018. Chemotherapy-induced peripheral neuropathy: evidence from genome-wide association studies and replication within multiple myeloma patients. BMC Cancer, 18(1), 820. doi.org/10.1186/s12885-018-4728-4

Mai, E. K., Haas, E.-M., Lücke, S., Löpprich, M., Kunz, C., Pritsch, M., Knaup-Gregori, P., Raab, M. S., Schlenzka, J., Bertsch, U., Hillengass, J.Goldschmidt, H., 2018. A systematic classification of death causes in multiple myeloma. Blood Cancer J, 8(3), 30. doi.org/10.1038/s41408-018-0068-5

Merz, M., Hielscher, T., Hoffmann, K., Seckinger, A., Hose, D., Raab, M. S., Hillengass, J., Jauch, A.Goldschmidt, H., 2018. Cytogenetic abnormalities in monoclonal gammopathy of undetermined significance. Leukemia, 32(12), 2717-2719. doi.org/10.1038/s41375-018-0202-1

Merz, M., Jauch, A., Hielscher, T., Bochtler, T., Schönland, S. O., Seckinger, A., Hose, D., Bertsch, U., Neben, K., Raab, M. S., Hillengass, J., Salwender, H., Blau, I. W., Lindemann, H.-W., Schmidt-Wolf, I. G. H., Scheid, C., Haenel, M., Weisel, K. C.Goldschmidt, H., 2018. Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma. Blood Adv, 2(1), 1-9. doi.org/10.1182/bloodadvances.2017013334

Mohr, M., Hose, D., Seckinger, A.Marciniak-Czochra, A., 2018. Quantification of plasma cell dynamics using mathematical modelling. R Soc Open Sci, 5(1), 170759. doi.org/10.1098/rsos.170759

Seckinger, A., Bähr-Ivacevic, T., Benes, V.Hose, D. (2018) RNA-Sequencing from Low-Input Material in Multiple Myeloma for Application in Clinical Routine, Multiple Myeloma. Methods in Molecular BiologyHumana Press, New York, NY, 97-115.

Seckinger, A., Hillengass, J., Emde, M., Beck, S., Kimmich, C., Dittrich, T., Hundemer, M., Jauch, A., Hegenbart, U., Raab, M.-S., Ho, A.D., Schönland, S., Hose, D., 2018b. CD38 as Immunotherapeutic Target in Light Chain Amyloidosis and Multiple Myeloma-Association With Molecular Entities, Risk, Survival, and Mechanisms of Upfront Resistance. Front Immunol 9, 1676. https://doi.org/10.3389/fimmu.2018.01676

Seehawer, M., Heinzmann, F., D'Artista, L., Harbig, J., Roux, P.-F., Hoenicke, L., Dang, H., Klotz, S., Robinson, L., Doré, G., Rozenblum, N., Kang, T.-W., Chawla, R., Buch, T., Vucur, M., Roth, M., Zuber, J., Luedde, T., Sipos, B., Longerich, T., Heikenwälder, M., Wang, X. W., Bischof, O.Zender, L., 2018. Necroptosis microenvironment directs lineage commitment in liver cancer. Nature. doi.org/10.1038/s41586-018-0519-y

Stoyan, D., Pommerening, A., Hummel, M.Kopp-Schneider, A., 2018. Multiple-rater kappas for binary data: Models and interpretation. Biom J, 60(2), 381-394. doi.org/10.1002/bimj.201600267

Sud, A., Thomsen, H., Orlando, G., Foersti, A., Law, P. J., Broderick, P., Cooke, R., Hariri, F., Pastinen, T., Easton, D. F., Pharoah, P. D. P., Dunning, A. M., Peto, J., Canzian, F., Eeles, R., Kote-Jarai, Z., Muir, K., Pashayan, N., Campa, D., Hoffmann, P., Noethen, M. M., Joeckel, K.-H., von Strandmann, E. P., Swerdlow, A. J., Engert, A., Orr, N., Hemminki, K.Houlston, R. S., 2018. Genome-wide association study implicates immune dysfunction in the development of Hodgkin lymphoma. Blood, 132(19), 2040-2052. doi.org/10.1182/blood-2018-06-855296

Went, M., Sud, A., Försti, A., Halvarsson, B.-M., Weinhold, N., Kimber, S., van Duin, M., Thorleifsson, G., Holroyd, A., Johnson, D. C., Li, N., Orlando, G., Law, P. J., Ali, M., Chen, B., Mitchell, J. S., Gudbjartsson, D. F., Kuiper, R., Stephens, O. W., Bertsch, U., Broderick, P., Campo, C., Bandapalli, O. R., Einsele, H., Gregory, W. A., Gullberg, U., Hillengass, J., Hoffmann, P., Jackson, G. H., Jöckel, K.-H., Johnsson, E., Kristinsson, S. Y., Mellqvist, U.-H., Nahi, H., Easton, D., Pharoah, P., Dunning, A., Peto, J., Canzian, F., Swerdlow, A., Eeles, R. A., Kote-Jarai, Z., Muir, K., Pashayan, N., Nickel, J., Nöthen, M. M., Rafnar, T., Ross, F. M., da Silva Filho, M. I., Thomsen, H., Turesson, I., Vangsted, A., Andersen, N. F., Waage, A., Walker, B. A., Wihlborg, A.-K., Broyl, A., Davies, F. E., Thorsteinsdottir, U., Langer, C., Hansson, M., Goldschmidt, H., Kaiser, M., Sonneveld, P., Stefansson, K., Morgan, G. J., Hemminki, K., Nilsson, B., Houlston, R. S.consortium, P., 2018. Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma. Nat Commun, 9(1), 3707. doi.org/10.1038/s41467-018-04989-w

Went, M., Sud, A., Speedy, H., Sunter, N. J., Försti, A., Law, P. J., Johnson, D. C., Mirabella, F., Holroyd, A., Li, N., Orlando, G., Weinhold, N., van Duin, M., Chen, B., Mitchell, J. S., Mansouri, L., Juliusson, G., Smedby, K. E., Jayne, S., Majid, A., Dearden, C., Allsup, D. J., Bailey, J. R., Pratt, G., Pepper, C., Fegan, C., Rosenquist, R., Kuiper, R., Stephens, O. W., Bertsch, U., Broderick, P., Einsele, H., Gregory, W. M., Hillengass, J., Hoffmann, P., Jackson, G. H., Jöckel, K.-H., Nickel, J., Nöthen, M. M., da Silva Filho, M. I., Thomsen, H., Walker, B. A., Broyl, A., Davies, F. E., Hansson, M., Goldschmidt, H., Dyer, M. J. S., Kaiser, M., Sonneveld, P., Morgan, G. J., Hemminki, K., Nilsson, B., Catovsky, D., Allan, J. M.Houlston, R. S., 2018. Genetic correlation between multiple myeloma and chronic lymphocytic leukaemia provides evidence for shared aetiology. Blood Cancer J, 9(1), 1. doi.org/10.1038/s41408-018-0162-8

Yadav, P., Merz, M., Mai, E. K., Försti, A., Jauch, A., Goldschmidt, H.Hemminki, K., 2018. Cytogenetic aberrations in multiple myeloma are associated with shifts in serum immunoglobulin isotypes distribution and levels. Haematologica, 103(4), e162-e164. doi.org/10.3324/haematol.2017.184226

2017

da Silva Filho, M.I., Försti, A., Weinhold, N., Meziane, I., Campo, C., Huhn, S., Nickel, J., Hoffmann, P., Nöthen, M.M., Jöckel, K.-H., Landi, S., Mitchell, J.S., Johnson, D., Morgan, G.J., Houlston, R., Goldschmidt, H., Jauch, A., Milani, P., Merlini, G., Rowcieno, D., Hawkins, P., Hegenbart, U., Palladini, G., Wechalekar, A., Schönland, S.O., Hemminki, K., 2017. Genome-wide association study of immunoglobulin light chain amyloidosis in three patient cohorts: comparison with myeloma. Leukemia 31, 1735–1742. doi.org/10.1038/leu.2016.387

De Veirman, K., De Beule, N., Maes, K., Menu, E., De Bruyne, E., De Raeve, H., Fostier, K., Moreaux, J., Kassambara, A., Hose, D., Heusschen, R., Eriksson, H., Vanderkerken, K., Van Valckenborgh, E., 2017. Extracellular S100A9 Protein in Bone Marrow Supports Multiple Myeloma Survival by Stimulating Angiogenesis and Cytokine Secretion. Cancer Immunol Res 5, 839–846. doi.org/10.1158/2326-6066.CIR-17-0192

Granzow, M., Hegenbart, U., Hinderhofer, K., Hose, D., Seckinger, A., Bochtler, T., Hemminki, K., Goldschmidt, H., Schönland, S.O., Jauch, A., 2017. Novel recurrent chromosomal aberrations detected in clonal plasma cells of light chain amyloidosis patients show potential adverse prognostic effect: first results from a genome-wide copy number array analysis. Haematologica 102, 1281–1290. doi.org/10.3324/haematol.2016.160721

Hummel, M., Edelmann, D., Kopp-Schneider, A., 2017. Clustering of samples and variables with mixed-type data. PLoS ONE 12, e0188274. doi.org/10.1371/journal.pone.0188274

Law, P.J., Sud, A., Mitchell, J.S., Henrion, M., Orlando, G., Lenive, O., Broderick, P., Speedy, H.E., Johnson, D.C., Kaiser, M., Weinhold, N., Cooke, R., Sunter, N.J., Jackson, G.H., Summerfield, G., Harris, R.J., Pettitt, A.R., Allsup, D.J., Carmichael, J., Bailey, J.R., Pratt, G., Rahman, T., Pepper, C., Fegan, C., von Strandmann, E.P., Engert, A., Försti, A., Chen, B., Filho, M.I. da S., Thomsen, H., Hoffmann, P., Noethen, M.M., Eisele, L., Jöckel, K.-H., Allan, J.M., Swerdlow, A.J., Goldschmidt, H., Catovsky, D., Morgan, G.J., Hemminki, K., Houlston, R.S., 2017. Genome-wide association analysis of chronic lymphocytic leukaemia, Hodgkin lymphoma and multiple myeloma identifies pleiotropic risk loci. Sci Rep 7, 41071. doi.org/10.1038/srep41071

Li, N., Johnson, D.C., Weinhold, N., Kimber, S., Dobbins, S.E., Mitchell, J.S., Kinnersley, B., Sud, A., Law, P.J., Orlando, G., Scales, M., Wardell, C.P., Försti, A., Hoang, P.H., Went, M., Holroyd, A., Hariri, F., Pastinen, T., Meissner, T., Goldschmidt, H., Hemminki, K., Morgan, G.J., Kaiser, M., Houlston, R.S., 2017. Genetic Predisposition to Multiple Myeloma at 5q15 Is Mediated by an ELL2 Enhancer Polymorphism. Cell Rep 20, 2556–2564. doi.org/10.1016/j.celrep.2017.08.062

McDonald, M.M., Reagan, M.R., Youlten, S.E., Mohanty, S.T., Seckinger, A., Terry, R.L., Pettitt, J.A., Simic, M.K., Cheng, T.L., Morse, A., Le, L.M.T., Abi-Hanna, D., Kramer, I., Falank, C., Fairfield, H., Ghobrial, I.M., Baldock, P.A., Little, D.G., Kneissel, M., Vanderkerken, K., Bassett, J.H.D., Williams, G.R., Oyajobi, B.O., Hose, D., Phan, T.G., Croucher, P.I., 2017. Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma. Blood 129, 3452–3464. doi.org/10.1182/blood-2017-03-773341

Merz, M., Jauch, A., Hielscher, T., Mai, E.K., Seckinger, A., Hose, D., Bertsch, U., Neben, K., Raab, M.S., Salwender, H., Blau, I.W., Lindemann, H.-W., Schmidt-Wolf, I., Scheid, C., Haenel, M., Weisel, K., Goldschmidt, H., Hillengass, J., 2017. Longitudinal fluorescence in situ hybridization reveals cytogenetic evolution in myeloma relapsing after autologous transplantation. Haematologica 102, 1432–1438. doi.org/10.3324/haematol.2017.168005

Meziane, I., Huhn, S., Filho, M.I. da S., Weinhold, N., Campo, C., Nickel, J., Hoffmann, P., Nöthen, M.M., Jöckel, K.-H., Landi, S., Mitchell, J.S., Johnson, D., Jauch, A., Morgan, G.J., Houlston, R., Goldschmidt, H., Milani, P., Merlini, G., Rowcieno, D., Hawkins, P., Hegenbart, U., Palladini, G., Wechalekar, A., Försti, A., Schönland, S.O., Hemminki, K., 2017. Genome-wide association study of clinical parameters in immunoglobulin light chain amyloidosis in three patient cohorts. Haematologica 102, e411–e414. doi.org/10.3324/haematol.2017.171108

Schmitt, M., Hückelhoven, A.G., Hundemer, M., Schmitt, A., Lipp, S., Emde, M., Salwender, H., Hänel, M., Weisel, K., Bertsch, U., Dürig, J., Ho, A.D., Blau, I.W., Goldschmidt, H., Seckinger, A., Hose, D., 2017. Frequency of expression and generation of T-cell responses against antigens on multiple myeloma cells in patients included in the GMMG-MM5 trial. Oncotarget 8, 84847–84862. doi.org/10.18632/oncotarget.11215

Seckinger, A., Delgado, J.A., Moser, S., Moreno, L., Neuber, B., Grab, A., Lipp, S., Merino, J., Prosper, F., Emde, M., Delon, C., Latzko, M., Gianotti, R., Lüoend, R., Murr, R., Hosse, R.J., Harnisch, L.J., Bacac, M., Fauti, T., Klein, C., Zabaleta, A., Hillengass, J., Cavalcanti-Adam, E.A., Ho, A.D., Hundemer, M., Miguel, J.F.S., Strein, K., Umaña, P., Hose, D., Paiva, B., Vu, M.D., 2017. Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment. Cancer Cell 0. doi.org/10.1016/j.ccell.2017.02.002

Stoyan, D., Pommerening, A., Hummel, M., Kopp-Schneider, A., 2017. Multiple-rater kappas for binary data: Models and interpretation. Biom J. doi.org/10.1002/bimj.201600267

Sud, A., Thomsen, H., Law, P.J., Försti, A., Filho, M.I. da S., Holroyd, A., Broderick, P., Orlando, G., Lenive, O., Wright, L., Cooke, R., Easton, D., Pharoah, P., Dunning, A., Peto, J., Canzian, F., Eeles, R., Kote-Jarai, Zs., Muir, K., Pashayan, N., PRACTICAL consortium, Hoffmann, P., Nöthen, M.M., Jöckel, K.-H., Strandmann, E.P. von, Lightfoot, T., Kane, E., Roman, E., Lake, A., Montgomery, D., Jarrett, R.F., Swerdlow, A.J., Engert, A., Orr, N., Hemminki, K., Houlston, R.S., 2017. Genome-wide association study of classical Hodgkin lymphoma identifies key regulators of disease susceptibility. Nat Commun 8, 1892. doi.org/10.1038/s41467-017-00320-1

Thomsen, H., Campo, C., Weinhold, N., da Silva Filho, M.I., Pour, L., Gregora, E., Vodicka, P., Vodickova, L., Hoffmann, P., Nöthen, M.M., Jöckel, K.-H., Langer, C., Hajek, R., Goldschmidt, H., Hemminki, K., Försti, A., 2017. Genomewide association study on monoclonal gammopathy of unknown significance (MGUS). Eur. J. Haematol. 99, 70–79. doi.org/10.1111/ejh.12892

Went, M., Sud, A., Law, P.J., Johnson, D.C., Weinhold, N., Försti, A., van Duin, M., Mitchell, J.S., Chen, B., Kuiper, R., Stephens, O.W., Bertsch, U., Campo, C., Einsele, H., Gregory, W.M., Henrion, M., Hillengass, J., Hoffmann, P., Jackson, G.H., Lenive, O., Nickel, J., Nöthen, M.M., da Silva Filho, M.I., Thomsen, H., Walker, B.A., Broyl, A., Davies, F.E., Langer, C., Hansson, M., Kaiser, M., Sonneveld, P., Goldschmidt, H., Hemminki, K., Nilsson, B., Morgan, G.J., Houlston, R.S., 2017. Assessing the effect of obesity-related traits on multiple myeloma using a Mendelian randomisation approach. Blood Cancer J 7, e573. doi.org/10.1038/bcj.2017.48

2016

Frank, C., Fallah, M., Chen, T., Mai, E.K., Sundquist, J., Försti, A., Hemminki, K., 2016. Search for familial clustering of multiple myeloma with any cancer. Leukemia 30, 627–632. doi.org/10.1038/leu.2015.279

Gietzelt, M., Höfer, T., Knaup-Gregori, P., König, R., Löpprich, M., Poos, A., Ganzinger, M., 2016. The Use of Tools, Modelling Methods, Data Types, and Endpoints in Systems Medicine: A Survey on Projects of the German e:Med-Programme. Stud Health Technol Inform 228, 670–674. doi.org/10.3233/978-1-61499-678-1-670

Gietzelt, M., Löpprich, M., Karmen, C., Knaup, P., Ganzinger, M., 2016. Models and Data Sources Used in Systems Medicine. A Systematic Literature Review. Methods Inf Med 55, 107–113. doi.org/10.3414/ME15-01-0151

Gu, C., Yang, Y., Sompallae, R., Xu, H., Tompkins, V.S., Holman, C., Hose, D., Goldschmidt, H., Tricot, G., Zhan, F., Janz, S., 2016. FOXM1 is a therapeutic target for high-risk multiple myeloma. Leukemia 30, 873–882. doi.org/10.1038/leu.2015.334

Johnson, D.C., Weinhold, N., Mitchell, J., Chen, B., Stephens, O.W., Försti, A., Nickel, J., Kaiser, M., Gregory, W.A., Cairns, D., Jackson, G.H., Hoffmann, P., Noethen, M.M., Hillengass, J., Bertsch, U., Barlogie, B., Davis, F.E., Hemminki, K., Goldschmidt, H., Houlston, R.S., Morgan, G.J., 2016. Genetic factors influencing the risk of multiple myeloma bone disease. Leukemia 30, 883–888. doi.org/10.1038/leu.2015.342

Johnson, D.C., Weinhold, N., Mitchell, J.S., Chen, B., Kaiser, M., Begum, D.B., Hillengass, J., Bertsch, U., Gregory, W.A., Cairns, D., Jackson, G.H., Försti, A., Nickel, J., Hoffmann, P., Nöethen, M.M., Stephens, O.W., Barlogie, B., Davis, F.E., Hemminki, K., Goldschmidt, H., Houlston, R.S., Morgan, G.J., 2016. Genome-wide association study identifies variation at 6q25.1 associated with survival in multiple myeloma. Nat Commun 7, 10290. doi.org/10.1038/ncomms10290

Mitchell, J.S., Li, N., Weinhold, N., Försti, A., Ali, M., van Duin, M., Thorleifsson, G., Johnson, D.C., Chen, B., Halvarsson, B.-M., Gudbjartsson, D.F., Kuiper, R., Stephens, O.W., Bertsch, U., Broderick, P., Campo, C., Einsele, H., Gregory, W.A., Gullberg, U., Henrion, M., Hillengass, J., Hoffmann, P., Jackson, G.H., Johnsson, E., Jöud, M., Kristinsson, S.Y., Lenhoff, S., Lenive, O., Mellqvist, U.-H., Migliorini, G., Nahi, H., Nelander, S., Nickel, J., Nöthen, M.M., Rafnar, T., Ross, F.M., da Silva Filho, M.I., Swaminathan, B., Thomsen, H., Turesson, I., Vangsted, A., Vogel, U., Waage, A., Walker, B.A., Wihlborg, A.-K., Broyl, A., Davies, F.E., Thorsteinsdottir, U., Langer, C., Hansson, M., Kaiser, M., Sonneveld, P., Stefansson, K., Morgan, G.J., Goldschmidt, H., Hemminki, K., Nilsson, B., Houlston, R.S., 2016. Genome-wide association study identifies multiple susceptibility loci for multiple myeloma. Nat Commun 7, 12050. doi.org/10.1038/ncomms12050

Weinhold, N., Kirn, D., Seckinger, A., Hielscher, T., Granzow, M., Bertsch, U., Egerer, G., Salwender, H., Blau, I.W., Weisel, K., Hillengass, J., Raab, M.S., Hose, D., Goldschmidt, H., Jauch, A., 2016. Concomitant gain of 1q21 and MYC translocation define a poor prognostic subgroup of hyperdiploid multiple myeloma. Haematologica 101, e116-119. doi.org/10.3324/haematol.2015.136929

2015

Bolomsky, A., Hose, D., Schreder, M., Seckinger, A., Lipp, S., Klein, B., Heintel, D., Ludwig, H., Zojer, N., 2015. Insulin like growth factor binding protein 7 (IGFBP7) expression is linked to poor prognosis but may protect from bone disease in multiple myeloma. J Hematol Oncol 8, 10. doi.org/10.1186/s13045-014-0105-1

Cowan, G., Weston-Bell, N.J., Bryant, D., Seckinger, A., Hose, D., Zojer, N., Sahota, S.S., 2015. Massive parallel IGHV gene sequencing reveals a germinal center pathway in origins of human multiple myeloma. Oncotarget 6, 13229–13240. doi.org/10.18632/oncotarget.3644

Fichtner, S., Hose, D., Engelhardt, M., Meißner, T., Neuber, B., Krasniqi, F., Raab, M., Schönland, S., Ho, A.D., Goldschmidt, H., Hundemer, M., 2015. Association of antigen-specific T-cell responses with antigen expression and immunoparalysis in multiple myeloma. Clin. Cancer Res. 21, 1712–1721. doi.org/10.1158/1078-0432.CCR-14-1618

Ganzinger, M., Gietzelt, M., Karmen, C., Firnkorn, D., Knaup, P., 2015a. An IT Architecture for Systems Medicine. Stud Health Technol Inform 210, 185–189. doi.org/10.3233/978-1-61499-512-8-185

Ganzinger, M., Haux, C., Karmen, C., Wetter, T., Knaup, P., 2015b. Systems Medicine for Multiple Myeloma: A Review on Decision Support Systems. Stud Health Technol Inform 216, 951. doi.org/10.3233/978-1-61499-564-7-951

Kuiper, R., van Duin, M., van Vliet, M.H., Broijl, A., van der Holt, B., El Jarari, L., van Beers, E.H., Mulligan, G., Avet-Loiseau, H., Gregory, W.M., Morgan, G., Goldschmidt, H., Lokhorst, H.M., Sonneveld, P., 2015. Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging System. Blood 126, 1996–2004. doi.org/10.1182/blood-2015-05-644039

Maes, K., De Smedt, E., Kassambara, A., Hose, D., Seckinger, A., Van Valckenborgh, E., Menu, E., Klein, B., Vanderkerken, K., Moreaux, J., De Bruyne, E., 2015. In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma. Oncotarget 6, 3319–3334. doi.org/10.18632/oncotarget.3207

Mai, E.K., Hielscher, T., Kloth, J.K., Merz, M., Shah, S., Raab, M.S., Hillengass, M., Wagner, B., Jauch, A., Hose, D., Weber, M.-A., Delorme, S., Goldschmidt, H., Hillengass, J., 2015. A magnetic resonance imaging-based prognostic scoring system to predict outcome in transplant-eligible patients with multiple myeloma. Haematologica 100, 818–825. doi.org/10.3324/haematol.2015.124115

Meißner, T., Seckinger, A., Hemminki, K., Bertsch, U., Foersti, A., Haenel, M., Duering, J., Salwender, H., Goldschmidt, H., Morgan, G.J., Hose, D., Weinhold, N., 2015. Profound impact of sample processing delay on gene expression of multiple myeloma plasma cells. BMC Med Genomics 8, 85. doi.org/10.1186/s12920-015-0161-6

Weinhold, N., Meissner, T., Johnson, D.C., Seckinger, A., Moreaux, J., Försti, A., Chen, B., Nickel, J., Chubb, D., Rawstron, A.C., Doughty, C., Dahir, N.B., Begum, D.B., Young, K., Walker, B.A., Hoffmann, P., Nöthen, M.M., Davies, F.E., Klein, B., Goldschmidt, H., Morgan, G.J., Houlston, R.S., Hose, D., Hemminki, K., 2015. The 7p15.3 (rs4487645) association for multiple myeloma shows strong allele-specific regulation of the MYC-interacting gene CDCA7L in malignant plasma cells. Haematologica 100, e110-113. http://doi.org/10.3324/haematol.2014.118786

2014

Ganzinger, M., Gietzelt, M., Karmen, C., Firnkorn, D., Knaup, P., 2015. An IT Architecture for Systems Medicine. Stud Health Technol Inform 210, 185–189. doi.org/10.3233/978-1-61499-512-8-185

Karmen, C., Ganzinger, M., Kohl, C.D., Firnkorn, D., Knaup-Gregori, P., 2014. A framework for integrating heterogeneous clinical data for a disease area into a central data warehouse. Stud Health Technol Inform 205, 1060–1064. doi.org/10.3233/978-1-61499-432-9-1060

Morgan, G.J., Johnson, D.C., Weinhold, N., Goldschmidt, H., Landgren, O., Lynch, H.T., Hemminki, K., Houlston, R.S., 2014. Inherited genetic susceptibility to multiple myeloma. Leukemia 28, 518–524. doi.org/10.1038/leu.2013.344

Weinhold, N., Försti, A., da Silva Filho, M.I., Nickel, J., Campo, C., Hoffmann, P., Nöthen, M.M., Hose, D., Goldschmidt, H., Jauch, A., Langer, C., Hegenbart, U., Schönland, S.O., Hemminki, K., 2014. Immunoglobulin light-chain amyloidosis shares genetic susceptibility with multiple myeloma. Leukemia 28, 2254–2256. doi.org/10.1038/leu.2014.208

Weinhold, N., Johnson, D.C., Rawstron, A.C., Försti, A., Doughty, C., Vijayakrishnan, J., Broderick, P., Dahir, N.B., Begum, D.B., Hosking, F.J., Yong, K., Walker, B.A., Hoffmann, P., Mühleisen, T.W., Langer, C., Dörner, E., Jöckel, K.-H., Eisele, L., Nöthen, M.M., Hose, D., Davies, F.E., Goldschmidt, H., Morgan, G.J., Hemminki, K., Houlston, R.S., 2014. Inherited genetic susceptibility to monoclonal gammopathy of unknown significance. Blood 123, 2513–2517; quiz 2593. doi.org/10.1182/blood-2013-10-532283

2013

Chubb, D., Weinhold, N., Broderick, P., Chen, B., Johnson, D.C., Försti, A., Vijayakrishnan, J., Migliorini, G., Dobbins, S.E., Holroyd, A., Hose, D., Walker, B.A., Davies, F.E., Gregory, W.A., Jackson, G.H., Irving, J.A., Pratt, G., Fegan, C., Fenton, J.A.L., Neben, K., Hoffmann, P., Nöthen, M.M., Mühleisen, T.W., Eisele, L., Ross, F.M., Straka, C., Einsele, H., Langer, C., Dörner, E., Allan, J.M., Jauch, A., Morgan, G.J., Hemminki, K., Houlston, R.S., Goldschmidt, H., 2013. Common variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influences multiple myeloma risk. Nat. Genet. 45, 1221–1225. doi.org/10.1038/ng.2733

Moehler, T.M., Seckinger, A., Hose, D., Andrulis, M., Moreaux, J., Hielscher, T., Willhauck-Fleckenstein, M., Merling, A., Bertsch, U., Jauch, A., Goldschmidt, H., Klein, B., Schwartz-Albiez, R., 2013. The glycome of normal and malignant plasma cells. PLoS ONE 8, e83719. doi.org/10.1371/journal.pone.0083719

 

CLIOMMICS-Projekte in den Medien: